Clinical Edge Journal Scan

Fluorescence optical imaging holds potential for detecting early signs of PsA


 

Key clinical point: This follow-up comparison of fluorescence optical imaging (FOI) with musculoskeletal ultrasound (MSUS) showed that FOI can be considered a useful screening tool for the early diagnosis of psoriatic arthritis (PsA).

Major finding: Patients diagnosed with PsA after the baseline evaluation had a higher prevalence of joints with pathological enhancement in FOI during follow-up ( P = .046), notably in phase 2 FOI ( P = .037). Similar to MSUS (area under the curve [AUC] 0.77), detecting newly affected joints by FOI (phase 2 in PrimaVista Mode; AUC 0.78) was positively linked with the shift of diagnosis from suspected to confirmed PsA.

Study details: In this follow-up study of 30 patients with psoriasis who had tender or swollen joints, the FOI of both the hands and the grayscale/power Doppler MSUS of the clinically dominant hand were compared.

Disclosures: This study was supported by the BMBF, German Ministry for Education and Research. The authors declared no conflict of interests.

Source: Buttner J et al. Follow-up comparison of fluorescence optical imaging with musculoskeletal ultrasound for early detection of psoriatic arthritis. Front Med. 2022;9:845545 (Mar 18). Doi: 10.3389/fmed.2022.845545

Recommended Reading

Hypocaloric diet controls joint activity in psoriatic arthritis – regardless of weight loss
MDedge Rheumatology
IL-17 inhibitors associated with higher treatment persistence in PsA
MDedge Rheumatology
Robust and sustained improvement with guselkumab in a diverse population of patients with PsA
MDedge Rheumatology
PsA: Rapid and sustained improvement in pain with upadacitinib
MDedge Rheumatology
Dermatological improvements translate to enhanced QoL in PsA
MDedge Rheumatology
Differential response to ixekizumab among males and females with PsA
MDedge Rheumatology
Factors associated with increased sleep disturbance in PsA
MDedge Rheumatology
Multimodal imaging of DIP-joint and SEC can help distinguish PsA from psoriasis or OA
MDedge Rheumatology
Large integrated safety analysis reinforces known safety profile of ixekizumab in PsA
MDedge Rheumatology
Guselkumab reduces collagen degradation biomarker levels associated with active PsA
MDedge Rheumatology